Lipoprotein(a) and the atherosclerotic burden – Should we wait for clinical trial evidence before taking action?

Lipoprotein(a) and the atherosclerotic burden – Should we wait for clinical trial evidence before taking action?

The fact that lipoprotein(a) levels should be regarded as a causal residual risk factor in the atherosclerotic cardiovascular diseases (ASCVD) is now a no-brainer. This review article aims to summarize the latest evidence supporting the causal role of lipoprotein(a) in ASCVD and the potential strate...

Full description

Saved in:
Bibliographic Details
Main Authors: Isabella Fichtner, Chiara Macchi, Alessandra Stefania Rizzuto, Stefano Carugo, Alberto Corsini, Massimiliano Ruscica
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:Atherosclerosis Plus
Subjects:
Lipoprotein(a)
Atherosclerotic cardiovascular risk
lipoprotein(a) measurements
Online Access:http://www.sciencedirect.com/science/article/pii/S2667089524000452
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items